These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 28290974)

  • 1. Sepsis Mimicker in an Human Immunodeficiency Virus-Infected Patient.
    Morgan MK; Hartzell JD; Blaylock JM
    Mil Med; 2017 Mar; 182(3):e1861-e1863. PubMed ID: 28290974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
    Tebas P; Sension M; Arribas J; Duiculescu D; Florence E; Hung CC; Wilkin T; Vanveggel S; Stevens M; Deckx H;
    Clin Infect Dis; 2014 Aug; 59(3):425-34. PubMed ID: 24729492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans.
    Dave JA; Cohen K; Micklesfield LK; Maartens G; Levitt NS
    PLoS One; 2015; 10(12):e0144286. PubMed ID: 26633015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired sperm motility in HIV-infected men: an unexpected adverse effect of efavirenz?
    Frapsauce C; Grabar S; Leruez-Ville M; Launay O; Sogni P; Gayet V; Viard JP; De Almeida M; Jouannet P; Dulioust E
    Hum Reprod; 2015 Aug; 30(8):1797-806. PubMed ID: 26085581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS Syndrome).
    Holbrook MB; Glick J
    J Emerg Med; 2019 May; 56(5):562-563. PubMed ID: 30879852
    [No Abstract]   [Full Text] [Related]  

  • 6. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
    Podany AT; Bao Y; Swindells S; Chaisson RE; Andersen JW; Mwelase T; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Kim P; Fletcher CV;
    Clin Infect Dis; 2015 Oct; 61(8):1322-7. PubMed ID: 26082504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with seminal impairment in HIV-infected men under antiretroviral therapy.
    Jerónimo A; Baza MB; Río I; Vera M; Hernando V; Castilla J; Rodriguez C; Del Romero J
    Hum Reprod; 2017 Feb; 32(2):265-271. PubMed ID: 28007791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Bayonne Kombo ES; Gathse A
    Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
    Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D
    Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
    Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
    N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of efavirenz and protease inhibitor based combination antiretroviral therapy regimens in treatment-naïve people living with HIV with baseline resistance.
    Lim C; McFaul K; Kabagambe S; Sonecha S; Jones R; Asboe D; Pozniak A; Nwokolo N; Boffito M
    AIDS; 2016 Jul; 30(11):1849-52. PubMed ID: 27139315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efavirenz-induced hypersensitivity reaction manifesting in rash and hepatitis in a Latino male.
    Leung JM; O'Brien JG; Wong HK; Winslow DL
    Ann Pharmacother; 2008 Mar; 42(3):425-9. PubMed ID: 18252833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypersensitivity to efavirenz treated with corticosteroids in a 6-year-old child.
    Foti JL; Piatt JP
    AIDS Patient Care STDS; 2003 Jan; 17(1):1-3. PubMed ID: 12614514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial.
    Firnhaber C; Smeaton LM; Grinsztejn B; Lalloo U; Faesen S; Samaneka W; Infante R; Rana A; Kumarasamy N; Hakim J; Campbell TB
    HIV Clin Trials; 2015; 16(3):89-99. PubMed ID: 25979186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 28-year-old woman with fever, rash, and pancytopenia.
    Ochoa S; Cheng K; Fleury CM; Luccioli S; Bellanti JA
    Allergy Asthma Proc; 2017 Jul; 38(4):322-327. PubMed ID: 28668113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.